Business Context and Reporting Period
Pacific Biosciences of California, Inc. filed this Form 8-K on February 5, 2013, to report the entry into a material definitive agreement. The Company, incorporated in Delaware, is based in Menlo Park, California.
Key Financial Metrics and Transaction Details
- Debt Financing: Entered into a Facility Agreement with Deerfield Management Company, L.P. affiliates for a principal amount of $20.5 million.
- Net Proceeds: Received $20.0 million after deducting a $500,000 facility fee.
- Interest Rate: Notes bear simple interest at 8.75% per annum, payable quarterly in arrears starting April 1, 2013.
- Term: Maximum term of seven years from the agreement date.
- Liquidity Covenant: Required to maintain consolidated cash and cash equivalents of not less than $2.0 million on the last day of each calendar quarter.
- Equity Component: Issued warrants to purchase 5,500,000 shares of Common Stock at an initial exercise price of $2.63 per share.
Material Changes and Covenants
This filing represents a significant change in the Company's capital structure through the incurrence of new debt and the issuance of warrants. Key covenants and conditions include:
- Sales Milestone: If Net Sales are less than $41 million for the twelve-month period from Q2 2014 through Q1 2015, one-third of the principal balance becomes due on the third, fourth, and fifth anniversaries of the agreement at Deerfield's option.
- Prepayment from Equity: The Company must apply 25% of net proceeds from future equity financings to repay the Notes, subject to exceptions (e.g., until 15,000,000 shares of Common Stock are issued post-agreement).
- Major Transactions: Deerfield has the option to require repayment upon a change of control or sale of substantially all assets.
- Security Interest: The Company granted a security interest in substantially all of its property to secure the obligations.
- Restrictions: The agreement includes customary restrictions on incurring additional indebtedness or liens.
Outlook, Risks, and Contingencies
The filing highlights several risks and contingencies associated with the financing:
- Event of Default: The principal balance may become immediately due and payable upon an Event of Default, requiring repayment of 100% of the principal plus accrued interest.
- Warrant Expiration: Warrants expire on the seventh anniversary of issuance and contain limitations preventing holders from acquiring more than 9.985% of outstanding shares upon exercise.
- Registration Rights: The Company is obligated to file a Form S-3 registration statement within 45 days to register the resale of shares underlying the warrants.
- Prepayment: The Facility Agreement does not provide for prepayment at the Company's option.
Investor Verification Checklist
- Verify the Company's ability to meet the $2.0 million quarterly cash and cash equivalents covenant.
- Monitor projected Net Sales to assess the risk of triggering the $41 million milestone repayment clause in 2014-2015.
- Review the impact of the 25% prepayment requirement on future equity fundraising efforts.
- Confirm the status of the Form S-3 registration statement filing for the warrant shares.
- Assess the dilution potential of the 5,500,000 warrants exercisable at $2.63 per share.